The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Hepatology. 2020 Jun 16. doi: 10.1002/hep.31420. Online ahead of print.
Zobair M Younossi12, Mary E Rinella3, Arun Sanyal4, Stephen A Harrison5, Elizabeth Brunt6, Zachary Goodman12, David E Cohen7, Rohit Loomba8
Author information
1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.
2Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA.
3Department of Medicine, Northwestern University Medical Center, Chicago, IL, USA.
4Division of Gastroenterology, Virginia Commonwealth University, Richmond, VA, USA.
5Pinnacle Clinical Research, San Antonio, TX, USA.
6Department of Pathology and Immunology, Washington University, St. Louis, MO, USA.
7Division of Gastroenterology and Hepatology, Weill Cornell Medical Center, New York, NY, USA.
8NAFLD Research Center, University of California at San Diego, La Jolla, CA, USA.
Abstract
The term nonalcoholic fatty liver disease (NAFLD) was initially introduced by Schaffner in 1986. NAFLD is a clinical entity characterized by the presence of hepatic steatosis affecting at least 5% of hepatocytes in individuals who consume little or no alcohol and who do not have a secondary cause of hepatic steatosis such as viral hepatitis, medications (such as tamoxifen, amiodarone and methotrexate, among others), or lipodystrophy.